H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Insmed to $70 from $52 and keeps a Buy rating on the shares. The analyst views the topline data from the ASPEN trial as positive yet will be looking to further analysis to provide more granularity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM: